| Host |
Rabbit |
| Klon |
ZR152 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
HIER or PIER |
| Positivkontrolle |
HCC |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant fragment (around aa400-600) of human HSPA1B protein |
| Lokalisation |
Nucleus and cytoplasm |
HSP70
|
Zeta Corporation |
ZR152 |
1 ml |
Concentrate |
CE/IVD |
Z2694RL |
-
|
| Host |
Rabbit |
| Klon |
ZR152 |
| Format |
ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
HIER or PIER |
| Positivkontrolle |
HCC |
| Verdünnung |
--- |
| Isotyp |
IgG |
| Verdünnung |
Recombinant fragment (around aa400-600) of human HSPA1B protein |
| Lokalisation |
Nucleus and cytoplasm |
HSP70
|
Zeta Corporation |
ZR152 |
7 ml |
ready-to-use |
CE/IVD |
Z2694RP |
-
|
| Host |
Rabbit |
| Klon |
ZR152 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
HIER or PIER |
| Positivkontrolle |
HCC |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant fragment (around aa400-600) of human HSPA1B protein |
| Lokalisation |
Nucleus and cytoplasm |
HSP70
|
Zeta Corporation |
ZR152 |
0.5 ml |
Concentrate |
CE/IVD |
Z2694RS |
-
|
| Host |
Rabbit |
| Klon |
ZR152 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
HIER or PIER |
| Positivkontrolle |
HCC |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant fragment (around aa400-600) of human HSPA1B protein |
| Lokalisation |
Nucleus and cytoplasm |
HSP70
|
Zeta Corporation |
ZR152 |
0.1 ml |
Concentrate |
CE/IVD |
Z2694RT |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Ready-to-use |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
HSV Infected Lung |
| Verdünnung |
- |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Cytoplasm, nucleus |
HSV I (Herpes Simplex Virus)
|
Diagnostic Biosystems |
polyclonal |
6 ml |
Ready-to-use |
CE/IVD |
PDR032 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
HSV Infected Lung |
| Verdünnung |
1:75 - 1:200 |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Cytoplasm, nucleus |
HSV I (Herpes Simplex Virus)
|
Diagnostic Biosystems |
polyclonal |
1 ml |
Concentrate |
CE/IVD |
RP018 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
HSV Infected Lung |
| Verdünnung |
1:75 - 1:200 |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Cytoplasm, nucleus |
HSV I (Herpes Simplex Virus)
|
Diagnostic Biosystems |
polyclonal |
0.1 ml |
Concentrate |
CE/IVD |
RP018-01 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
HSV Infected Lung |
| Verdünnung |
1:75 - 1:200 |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Cytoplasm, nucleus |
HSV I (Herpes Simplex Virus)
|
Diagnostic Biosystems |
polyclonal |
0.5 ml |
Concentrate |
CE/IVD |
RP018-05 |
-
|
| Host |
Rabbit + Mouse |
| Klon |
polyclonal + DBM15.69 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
HSV Infected Tissue |
| Verdünnung |
- |
| Isotyp |
Rabbit Ig + Mouse IgG1 |
| Verdünnung |
Whole rabbit corneal cells, infected with herpes simplex virus type I (strain Mac Intyre) and BALB/C mice immunized with Parker strain of herpes simplex virus type 2. |
| Lokalisation |
Cytoplasm, nucleus |
HSV I & II (Herpes Simplex Virus)
|
Diagnostic Biosystems |
polyclonal + DBM15.69 |
6 ml |
Ready-to-use |
CE/IVD |
PDRM001 |
-
|
| Host |
Mouse |
| Klon |
0192 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
HSV infected tissue |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
IgG1 |
| Verdünnung |
Synthesized peptide specific to glycoprotein D |
| Lokalisation |
Cytoplasm or nucleus |
HSV II
|
Zeta Corporation |
0192 |
1ml |
Concentrate |
RUO |
Z2831ML-R |
-
|
| Host |
Mouse |
| Klon |
DBM15.69 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Infected lung |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
IgG1 |
| Verdünnung |
BALB/C mice were immunized with Parker strain of herpes simplex virus type 2 |
| Lokalisation |
Cytoplasm, nucleus |
HSV II (Herpes simplex Virus)
|
Diagnostic Biosystems |
DBM15.69 |
1 ml |
Concentrate |
CE/IVD |
MOB542 |
-
|
| Host |
Mouse |
| Klon |
DBM15.69 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Infected lung |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
IgG1 |
| Verdünnung |
BALB/C mice were immunized with Parker strain of herpes simplex virus type 2 |
| Lokalisation |
Cytoplasm, nucleus |
HSV II (Herpes simplex Virus)
|
Diagnostic Biosystems |
DBM15.69 |
0.1 ml |
Concentrate |
CE/IVD |
MOB542-01 |
-
|
| Host |
Mouse |
| Klon |
DBM15.69 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Infected lung |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
IgG1 |
| Verdünnung |
BALB/C mice were immunized with Parker strain of herpes simplex virus type 2 |
| Lokalisation |
Cytoplasm, nucleus |
HSV II (Herpes simplex Virus)
|
Diagnostic Biosystems |
DBM15.69 |
0.5 ml |
Concentrate |
CE/IVD |
MOB542-05 |
-
|
| Host |
Mouse |
| Klon |
DBM15.69 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Infected lung |
| Verdünnung |
- |
| Isotyp |
IgG1 |
| Verdünnung |
BALB/C mice were immunized with Parker strain of herpes simplex virus type 2 |
| Lokalisation |
Cytoplasm, nucleus |
HSV II (Herpes simplex Virus)
|
Diagnostic Biosystems |
DBM15.69 |
6 ml |
Ready-to-use |
CE/IVD |
PDM542 |
-
|
| Host |
Mouse |
| Klon |
DBM15.69 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Infected lung |
| Verdünnung |
- |
| Isotyp |
IgG1 |
| Verdünnung |
BALB/C mice were immunized with Parker strain of herpes simplex virus type 2 |
| Lokalisation |
Cytoplasm, nucleus |
HSV II (Herpes simplex Virus)
|
Diagnostic Biosystems |
DBM15.69 |
25 ml |
Ready-to-use |
CE/IVD |
PDM542-25 |
-
|
| Host |
Mouse |
| Klon |
10A3 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
HSV infected tissue |
| Verdünnung |
1:50 - 1:200 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
etergent-solubilized herpes simplex virus (HSV) type 1 infected cells |
| Lokalisation |
Cytoplasm or nucleus |
HSV1
|
Zeta Corporation |
10A3 |
1ml |
Concentrate |
CE/IVD |
Z2215ML |
-
|
| Host |
Mouse |
| Klon |
10A3 |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
HSV infected tissue |
| Verdünnung |
- |
| Isotyp |
IgG1 /κ |
| Verdünnung |
etergent-solubilized herpes simplex virus (HSV) type 1 infected cells |
| Lokalisation |
Cytoplasm or nucleus |
HSV1
|
Zeta Corporation |
10A3 |
7 ml |
Ready-to-use |
CE/IVD |
Z2215MP |
-
|
| Host |
Mouse |
| Klon |
10A3 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
HSV infected tissue |
| Verdünnung |
1:50 - 1:200 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
etergent-solubilized herpes simplex virus (HSV) type 1 infected cells |
| Lokalisation |
Cytoplasm or nucleus |
HSV1
|
Zeta Corporation |
10A3 |
0.5 ml |
Concentrate |
CE/IVD |
Z2215MS |
-
|
| Host |
Mouse |
| Klon |
10A3 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
HSV infected tissue |
| Verdünnung |
1:50 - 1:200 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
etergent-solubilized herpes simplex virus (HSV) type 1 infected cells |
| Lokalisation |
Cytoplasm or nucleus |
HSV1
|
Zeta Corporation |
10A3 |
0.1 ml |
Concentrate |
CE/IVD |
Z2215MT |
-
|
| Host |
Mouse |
| Klon |
AIF1 |
| Format |
concentrate |
| Methode |
F, P |
| Vorbehandlung |
Tris EDTA Puffer, pH 9,0 |
| Positivkontrolle |
Spleen |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
Mouse IgG1,kappa |
| Verdünnung |
Purified fragment of human recombinant AIF1 protein (around aa 1-146) (exact sequence is proprietary) |
| Lokalisation |
Cytoplasmic and Cell Surface |
Iba1 (AIF1)
|
Diagnostic Biosystems |
AIF1 |
1 ml |
concentrate |
CE/IVD |
MOB602 |
-
|
| Host |
Mouse |
| Klon |
AIF1 |
| Format |
ready-to-use |
| Methode |
F, P |
| Vorbehandlung |
Tris EDTA Puffer, pH 9,0 |
| Positivkontrolle |
Spleen |
| Verdünnung |
--- |
| Isotyp |
Mouse IgG1,kappa |
| Verdünnung |
Purified fragment of human recombinant AIF1 protein (around aa 1-146) (exact sequence is proprietary) |
| Lokalisation |
Cytoplasmic and Cell Surface |
Iba1 (AIF1)
|
Diagnostic Biosystems |
AIF1 |
6 ml |
ready-to-use |
CE/IVD |
PDM602 |
-
|
| Host |
Mouse |
| Klon |
IHC132 |
| Format |
concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Astrocytoma |
| Verdünnung |
1:100 |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cytoplasmic |
IDH1 R132H
|
Biocare Medical |
IHC132 |
0.1 ml |
concentrate |
CE/IVD |
ACI3253A |
-
|
| Host |
Mouse |
| Klon |
IHC132 |
| Format |
concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Astrocytoma |
| Verdünnung |
1:100 |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cytoplasmic |
IDH1 R132H
|
Biocare Medical |
IHC132 |
1 ml |
concentrate |
CE/IVD |
ACI3253C |
-
|
| Host |
Mouse |
| Klon |
IHC132 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Astrocytoma |
| Verdünnung |
- |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cytoplasmic |
IDH1 R132H
|
Biocare Medical |
IHC132 |
7 ml |
Ready-to-use |
CE/IVD |
ALI3253G7 |
-
|
| Host |
Mouse |
| Klon |
IHC132 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Astrocytoma |
| Verdünnung |
- |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cytoplasmic |
IDH1 R132H
|
Biocare Medical |
IHC132 |
6 ml |
Ready-to-use |
CE/IVD |
API3253AA |
-
|
| Host |
Mouse |
| Klon |
HMab-1 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Human Glioma Tissue |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
Mouse IgG1 kappa |
| Lokalisation |
Cytoplasmic, nucleus |
IDH1 R132H
|
Diagnostic Biosystems |
HMab-1 |
1 ml |
Concentrate |
RUO |
MOB580R |
-
|
| Host |
Mouse |
| Klon |
HMab-1 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Human Glioma Tissue |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
Mouse IgG1 kappa |
| Lokalisation |
Cytoplasmic, nucleus |
IDH1 R132H
|
Diagnostic Biosystems |
HMab-1 |
0.1 ml |
Concentrate |
RUO |
MOB580R-01 |
-
|
| Host |
Mouse |
| Klon |
HMab-1 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Human Glioma Tissue |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
Mouse IgG1 kappa |
| Lokalisation |
Cytoplasmic, nucleus |
IDH1 R132H
|
Diagnostic Biosystems |
HMab-1 |
0.5 ml |
Concentrate |
RUO |
MOB580R-05 |
-
|
| Host |
Mouse |
| Klon |
HMab-1 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Human Glioma Tissue |
| Verdünnung |
- |
| Isotyp |
Mouse IgG1 kappa |
| Lokalisation |
Cytoplasmic, nucleus |
IDH1 R132H
|
Diagnostic Biosystems |
HMab-1 |
6 ml |
Ready-to-use |
RUO |
PDM580R |
-
|
| Host |
Mouse |
| Klon |
SMab-1 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Human Glioma Tissue |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
Mouse IgG1 kappa |
| Lokalisation |
Cytoplasmic, nucleus |
IDH1 R132S
|
Diagnostic Biosystems |
SMab-1 |
1 ml |
Concentrate |
RUO |
MOB582R |
-
|
| Host |
Mouse |
| Klon |
SMab-1 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Human Glioma Tissue |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
Mouse IgG1 kappa |
| Lokalisation |
Cytoplasmic, nucleus |
IDH1 R132S
|
Diagnostic Biosystems |
SMab-1 |
0.1 ml |
Concentrate |
RUO |
MOB582R-01 |
-
|
| Host |
Mouse |
| Klon |
SMab-1 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Human Glioma Tissue |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
Mouse IgG1 kappa |
| Lokalisation |
Cytoplasmic, nucleus |
IDH1 R132S
|
Diagnostic Biosystems |
SMab-1 |
0.5 ml |
Concentrate |
RUO |
MOB582R-05 |
-
|
| Host |
Mouse |
| Klon |
SMab-1 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Human Glioma Tissue |
| Verdünnung |
- |
| Isotyp |
Mouse IgG1 kappa |
| Lokalisation |
Cytoplasmic, nucleus |
IDH1 R132S
|
Diagnostic Biosystems |
SMab-1 |
6 ml |
Ready-to-use |
RUO |
PDM582R |
-
|
| Host |
Sheep |
| Klon |
polyclonal |
| Format |
Purified |
| Methode |
WB, P |
| Vorbehandlung |
Citrate |
| Isotyp |
Sheep IgG |
| Verdünnung |
Recombinant human indoleamine 2,3 - dioxygenase |
IDO (Indoleamine 2,3-Dioxygenase)
|
Zytomed Systems GmbH |
polyclonal |
100 µl |
Purified |
RUO |
609-0003 |
-
|
| Host |
Mouse |
| Klon |
UMAB126 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:100 |
| Isotyp |
IgG1 |
| Lokalisation |
Membrane, Cytoplasm |
IDO1
|
Biocare Medical |
UMAB126 |
0.1 ml |
Concentrate |
CE/IVD |
ACI3210A |
-
|
| Host |
Mouse |
| Klon |
UMAB126 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:100 |
| Isotyp |
IgG1 |
| Lokalisation |
Membrane, Cytoplasm |
IDO1
|
Biocare Medical |
UMAB126 |
0.5 ml |
Concentrate |
CE/IVD |
ACI3210B |
-
|
| Host |
Mouse |
| Klon |
UMAB126 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
- |
| Isotyp |
IgG1 |
| Lokalisation |
Membrane, Cytoplasm |
IDO1
|
Biocare Medical |
UMAB126 |
6 ml |
Ready-to-use |
CE/IVD |
API3210AA |
-
|
| Host |
Rabbit |
| Klon |
ZR291 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
? |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
? |
| Lokalisation |
? |
IgA
|
Zeta Corporation |
ZR291 |
1 ml |
Concentrate |
CE/IVD |
Z2729RL |
-
|
| Host |
Rabbit |
| Klon |
ZR291 |
| Format |
r-t-u |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
? |
| Verdünnung |
- |
| Isotyp |
IgG |
| Verdünnung |
? |
| Lokalisation |
? |
IgA
|
Zeta Corporation |
ZR291 |
7 ml |
r-t-u |
CE/IVD |
Z2729RP |
-
|
| Host |
Rabbit |
| Klon |
ZR291 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
? |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
? |
| Lokalisation |
? |
IgA
|
Zeta Corporation |
ZR291 |
0.5 ml |
Concentrate |
CE/IVD |
Z2729RS |
-
|
| Host |
Rabbit |
| Klon |
ZR291 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
? |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
? |
| Lokalisation |
? |
IgA
|
Zeta Corporation |
ZR291 |
0.1 ml |
Concentrate |
CE/IVD |
Z2729RT |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Methode |
F, P |
| Verdünnung |
1:20 - 1:40 |
| Isotyp |
Rabbit Ig |
IgA-FITC
|
Diagnostic Biosystems |
polyclonal |
1 ml |
Concentrate |
CE/IVD |
F007 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Methode |
F, P |
| Verdünnung |
1:20 - 1:40 |
| Isotyp |
Rabbit Ig |
IgA-FITC
|
Diagnostic Biosystems |
polyclonal |
0.1 ml |
Concentrate |
CE/IVD |
F007-01 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Ready-to-use |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
- |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Cytoplasm |
IgA, Human
|
Diagnostic Biosystems |
polyclonal |
6 ml |
Ready-to-use |
CE/IVD |
PDR017 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:25 - 1:100 |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Cytoplasm |
IgA, Human
|
Diagnostic Biosystems |
polyclonal |
1 ml |
Concentrate |
CE/IVD |
RP020 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:25 - 1:100 |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Cytoplasm |
IgA, Human
|
Diagnostic Biosystems |
polyclonal |
0.1 ml |
Concentrate |
CE/IVD |
RP020-01 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:25 - 1:100 |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Cytoplasm |
IgA, Human
|
Diagnostic Biosystems |
polyclonal |
0.5 ml |
Concentrate |
CE/IVD |
RP020-05 |
-
|
| Host |
Goat |
| Klon |
polyclonal |
| Format |
Purified |
| Methode |
F, WB, EL |
| Isotyp |
Goat IgG |
| Verdünnung |
Native human IgA |
IgA, Human (Alpha Chain)
|
Zytomed Systems GmbH |
polyclonal |
1 mg |
Purified |
RUO |
609-0062 |
-
|
| Host |
Mouse |
| Klon |
Mc29-12 |
| Format |
Purified |
| Methode |
F, P, EL |
| Isotyp |
Mouse IgG1 |
IgA, Human (Secretory Component)
|
Zytomed Systems GmbH |
Mc29-12 |
200 µg |
Purified |
RUO |
609-0066 |
-
|
| Host |
Rabbit |
| Klon |
ZR156 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Lymph node |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
Full-length human IGHD protein |
| Lokalisation |
Cytoplasm |
IgD (ZR156)
|
Zeta Corporation |
ZR156 |
1 ml |
Concentrate |
CE/IVD |
Z2696RL |
-
|